Ye Yun, Yuan Xiao-Hua, Wang Jian-Jun, Wang Yu-Chen, Li Su-Liang
Department of Laboratory Medicine.
Emergency Department, The First Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi, China.
Medicine (Baltimore). 2020 May 29;99(22):e19993. doi: 10.1097/MD.0000000000019993.
miR-141 has gradually demonstrated its value in the diagnosis of prostate cancer. However, the diagnostic parameters in previous studies differ. A systematic review was conducted to explore the diagnostic value of miR-141 in prostate cancer.
A comprehensive search of the literature in the PubMed, Medline, Cochrane Library, and Embase databases was performed. The included 7 studies assessed the diagnostic value of miR-141 in patients with prostate cancer up to October 31, 2019. We used meta-disc version 1.4 and STATA software version 12.0 to analyze the data.
The pooled sensitivity and specificity were 0.70 (95% confidence interval [CI] 0.64-0.75) and 0.73 (95% CI 0.64-0.80), respectively. The positive likelihood ratio was 2.88 (95% CI 1.40-5.93), and the negative likelihood ratio was 0.38 (95% CI 0.20-0.71). Further, we note that the pooled diagnostic odds ratio of miR-141 for prostate cancer was 9.94 (95% CI: 2.55-38.80). The summary area under the receiver operating characteristic curve was 0.83 (95% CI: 0.79-0.86). The results of meta-regression suggested that heterogeneity was mainly derived from patient age. The results of the Fagan nomogram showed that it was increased significantly by testing miR-141 for diagnosing prostate cancer.
This meta-analysis suggests that miR-141 has a high diagnostic value for prostate cancer. In the future, large-scale prospective studies are needed to verify and evaluate this result.
miR-141已逐渐在前列腺癌的诊断中展现出其价值。然而，先前研究中的诊断参数存在差异。本研究进行了一项系统评价，以探讨miR-141在前列腺癌中的诊断价值。
全面检索了PubMed、Medline、Cochrane图书馆和Embase数据库中的文献。纳入的7项研究评估了截至2019年10月31日miR-141在前列腺癌患者中的诊断价值。我们使用meta-disc 1.4版和STATA 12.0版软件分析数据。
合并敏感度和特异度分别为0.70（95%置信区间[CI] 0.64 - 0.75）和0.73（95% CI 0.64 - 0.80）。阳性似然比为2.88（95% CI 1.40 - 5.93），阴性似然比为0.38（95% CI 0.20 - 0.71）。此外，我们注意到miR-141对前列腺癌的合并诊断比值比为9.94（95% CI：2.55 - 38.80）。受试者工作特征曲线下的汇总面积为0.83（95% CI：0.79 - 0.86）。meta回归结果表明，异质性主要源于患者年龄。Fagan列线图结果显示，检测miR-141诊断前列腺癌时其显著增加。
本荟萃分析表明，miR-141对前列腺癌具有较高的诊断价值。未来，需要大规模的前瞻性研究来验证和评估这一结果。
